Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions
Publication
, Journal Article
Pollack, C; Reilly, PA; Verhamme, P; Bernstein, R; Dubiel, R; Eikelboom, J; Huisman, M; Hylek, E; Kam, C-W; Kamphuisen, PW; Kreuzer, J ...
Published in: JOURNAL OF THROMBOSIS AND HAEMOSTASIS
June 1, 2015
Duke Scholars
Published In
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
EISSN
1538-7836
ISSN
1538-7933
Publication Date
June 1, 2015
Volume
13
Start / End Page
85 / 85
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology
Citation
APA
Chicago
ICMJE
MLA
NLM
Pollack, C., Reilly, P. A., Verhamme, P., Bernstein, R., Dubiel, R., Eikelboom, J., … Weitz, J. (2015). Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. JOURNAL OF THROMBOSIS AND HAEMOSTASIS, 13, 85–85.
Pollack, C., P. A. Reilly, P. Verhamme, R. Bernstein, R. Dubiel, J. Eikelboom, M. Huisman, et al. “Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions.” JOURNAL OF THROMBOSIS AND HAEMOSTASIS 13 (June 1, 2015): 85–85.
Pollack C, Reilly PA, Verhamme P, Bernstein R, Dubiel R, Eikelboom J, et al. Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. 2015 Jun 1;13:85–85.
Pollack, C., et al. “Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions.” JOURNAL OF THROMBOSIS AND HAEMOSTASIS, vol. 13, WILEY-BLACKWELL, June 2015, pp. 85–85.
Pollack C, Reilly PA, Verhamme P, Bernstein R, Dubiel R, Eikelboom J, Huisman M, Hylek E, Kam C-W, Kamphuisen PW, Kreuzer J, Levy JH, Sellke F, Steiner T, Wang B, Weitz J. Initial results of the re-verse AD trial: idarucizumab reverses the anticoagulant effects of dabigatran in patients in an emergency setting of major bleeding, urgent surgery, or interventions. JOURNAL OF THROMBOSIS AND HAEMOSTASIS. WILEY-BLACKWELL; 2015 Jun 1;13:85–85.
Published In
JOURNAL OF THROMBOSIS AND HAEMOSTASIS
EISSN
1538-7836
ISSN
1538-7933
Publication Date
June 1, 2015
Volume
13
Start / End Page
85 / 85
Publisher
WILEY-BLACKWELL
Related Subject Headings
- Cardiovascular System & Hematology
- 3202 Clinical sciences
- 3201 Cardiovascular medicine and haematology
- 1103 Clinical Sciences
- 1102 Cardiorespiratory Medicine and Haematology